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Abstract 
The lymphedema diagnostic method used in descriptive or intervention studies may influence 
results found. The purposes of this work were to compare baseline lymphedema prevalence in 
the Physical Activity and Lymphedema (PAL) trial cohort and to subsequently compare the 
effect of the weight lifting intervention on lymphedema, according to four standard diagnostic 
methods. The PAL trial was a randomized, controlled intervention study, involving 295 women 
who had previously been treated for breast cancer, and evaluated the effect of 12 months of 
weight lifting on lymphedema status. Four diagnostic methods were used to evaluate 
lymphedema outcomes: interlimb volume difference via water displacement, interlimb size 
difference via sum of arm circumferences, interlimb impedance ratio using bioimpedance 
spectroscopy and a validated self-report survey. Of the 295 women who participated in the PAL 
trial, between 22-52% were considered to have lymphedema at baseline according to the four 
diagnostic criteria used. No between group differences were noted in the proportion of women 
who had a change in interlimb volume, interlimb size, interlimb ratio, or survey score of >5%, 
>5%, >10% and 1 unit, respectively (Cumulative incidence ratio at study end for each measure 
ranged between 0.6-0.8, with confidence intervals spanning 1.0). The variation in proportions of 
women within the PAL trial considered to have lymphoedema at baseline highlights the potential 
impact of the diagnostic criteria on population surveillance regarding prevalence of this common 
morbidity of treatment.  Importantly though, progressive weight lifting was shown to be safe for 
women following breast cancer, even for those at risk- or with lymphedema, irrespective of the 
diagnostic criteria used.   
 
Keywords: lymphedema, breast cancer, strength training, diagnostic methods, randomized 
controlled trial 
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BACKGROUND 
Breast cancer is the most common malignancy among women in the United States, with an 
estimate of 182,460 cases per year [1]. Due to early detection and improved treatment 
interventions, 5-year survival is achieved by almost 97% of women diagnosed with early stages 
of the disease [2,3]. Therefore, increasing attention has shifted to survivorship concerns that 
have significant impact on the quality of life [4] and cost of health care [5] following breast 
cancer and its associated treatment.  Lymphedema is one such treatment-related sequelae. 
 
Lymphedema secondary to breast cancer is caused by the disruption of the lymphatic system 
that in the initial stages, leads to the accumulation of fluid in the interstitial tissue space and 
eventually is clinically presented as swelling of the arm, shoulder, neck or torso [6,7]. Later 
stages of lymphedema are characterized by deposition of fibrotic and adipose tissue [8], making 
treatment with more conservative measures difficult [9].  At least 20% of women develop 
lymphedema following treatment for breast cancer and while those with more extensive lymph 
node dissection are at an increased risk, known risk factors (including but not limited to extent of 
lymph node dissection) do not fully distinguish the at-risk population [10]. Further, while 
lymphedema most commonly presents within 2 years of a breast cancer diagnosis [10-12], new 
cases may develop long after treatment has been completed. The physical, psychological and 
social consequences associated with lymphedema are considered profound, impacting all 
aspects of daily living [5].     
 
There exists no gold standard for the measurement of lymphedema, yet it is well established 
that the chosen diagnostic method used in a given observational or intervention study influences 
the results found [13-15]. Water displacement, perometry, and circumferences are 
lymphoedema assessment methods commonly used in clinical practice and research. These 
methods assess limb size as opposed to extracellular fluid and therefore are indirect measures 
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of early lymphedema [16]. In contrast, bioimpedance spectroscopy directly assesses 
extracellular fluid [16], but has limitations in detecting non-pitting, later-stage, edema, whereby 
fluid increases have been replaced by deposition of adipose tissue and/or fibrotic tissue. Self-
report methods take into account perceived size changes as well as presence and intensity of 
related symptoms. However, the presence of upper-body symptoms such as pain, weakness, 
tingling and heaviness are common in women following breast cancer, irrespective of 
lymphedema status, challenging the construct validity and therefore making its use as a 
diagnostic tool problematic [17].   
 
The PAL trial was a randomized, controlled study of twice-weekly progressive weight lifting over 
a 12 month period, involving 295 female breast cancer survivors, 141 of whom had stable 
lymphedema at baseline.  Lymphedema status was assessed using various standard diagnostic 
criteria, including objective and self-report measures. Results derived from the water 
displacement diagnostic method, clinical evaluation, and symptom changes have been 
previously reported.  Specifically, among the 141 women with lymphedema at baseline, weight 
lifting did not exacerbate existing lymphedema, significantly reduced risk of the need for 
therapist delivered treatment by half, and significantly decreased symptom severity [18]. Among 
the 154 women without lymphedema at baseline, weight lifting did not pose risk of lymphedema 
onset [19]. These findings contribute to the evidence-base demonstrating exercise is safe 
following breast cancer among those with or at-risk of lymphedema.  However, given that prior 
recommendations have been to avoid lifting and/or repetitive lifting with the affected arm 
following treatment for breast cancer and in recognition that the use of various lymphedema 
diagnostic methods may influence results found, it is paramount to evaluate the robustness of 
these findings. Therefore, the purposes of this work were to identify the baseline prevalence of 
lymphedema in the PAL cohort according to three standard diagnostic methods commonly used 
5 
 
in clinical practice and/or research, and to subsequently compare the effect of the weight lifting 
intervention on lymphedema outcomes using these same three diagnostic methods.  
 
METHODS: 
Participants: 
Description of the PAL study design and methods have been reported in detail elsewhere [20].   
Briefly, a total of 295 female breast cancer survivors were recruited between October 2005 and 
February 2007.  Women were eligible to participate if they had a history of unilateral non-
metastatic breast cancer, body mass index ≤ 50 Kg/m2, at least one excised lymph node, had 
no recurrence of breast cancer and had no clinical signs and symptoms of breast cancer at the 
time of recruitment.  A woman with stable lymphedema was eligible to participate.  For the 
purposes of the PAL trial, a woman was considered to have lymphedema if she: 1) had ≥ 10% 
inter-limb discrepancy in volume or circumference at the point of greatest visible difference or 
swelling or obstruction of the anatomic architecture on close inspection or pitting edema; or 2) 
had a prior clinical diagnosis of lymphedema and having had any prior intensive lymphedema 
therapy on the affected arm; or 3) self reported a clinical diagnosis of lymphedema which was 
later confirmed by study measurements or confirmed by a qualified clinician.  A woman was 
considered to have unstable lymphedema, and thus was excluded, if she: 1) needed intensive 
lymphedema therapy within three months before entry into the study; 2) had a 10% change in 
volume or circumference of the affected arm that had lasted at least seven days within three 
months before entry into the study; 3) experienced a lymphedema-related infection that required 
use of antibiotics within three months before entry into the study; or 4) required a change in 
activities of daily living in response to exacerbation of lymphedema within three months before 
entry into the study.   
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The study was approved by the Institutional Review Board of the University of Pennsylvania and 
is in full compliance with the U.S. Congress Health Insurance Portability and Accountability Act 
(HIPPA) of 1996.   
 
Measurements 
While study participants were defined as having lymphedema or not according to the PAL trial 
definition as outlined above, women’s lymphedema status at baseline and 12 months was also 
evaluated using four independent standardized methods, specifically volumetric, sum of arm 
circumferences, bioimpedance spectroscopy and a validated self-report survey.  Volumetric 
measures required participants to submerge their arms and hands in water, with the volume of 
displaced water being used to assess limb volume. When the volume of the treated side is >5% 
of the untreated side, lymphedema is considered clinically evident [7]. Circumference measures 
at the metacarpal, wrist and every 4cm along the arm until the axillary fold, were taken with 
women seated and arm resting on a bench in 90 degrees abduction.  When the sum of arm 
circumferences for the treated side was >5% of the sum of circumferences for the untreated 
side, the size difference was considered indicative of lymphedema.  Bioimpedance 
spectroscopy (Impedimed, San Diego, CA) was used to measure the impedance of the 
extracellular fluid of the treated and untreated arms, separately, with the impedance scores then 
being compared. When the ratio of impedance (R0 values) exceeds 3 standard deviations of 
normative values (>1.139 when treated on the dominant side, >1.066 when treated on the non-
dominant side) [21], lymphedema is considered clinically evident.  Participants were also asked 
to complete the validated Norman Lymphedema Survey [22], which asked women whether their 
hand, lower-arm and/or upper-arm (asked separately for the right and left sides) differed in size.  
If yes, then participants were further questioned regarding the degree of difference (1: very 
slight; “you are the only person who would notice this"; 2: “noticeable to people who know you 
well but not to strangers"; or 3: “very noticeable”).  The degree score was summed over the 
three locations and could range from 0 to 9. Women were then classified as having no 
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lymphedema (score of 0) or having evidence of any lymphedema (score of 1-9).  Mild 
lymphedema was classified by a score of 1-3, while moderate to severe lymphedema was 
classified by a score of 4-9.  Prior publications from the PAL trial have reported on a separate 
section of the Norman Lymphedema survey which asks patients to report on the presence and 
severity of any one of 14 possible common symptoms associated with lymphedema [18]. 
 
Statistical Analysis  
Descriptive statistics of all women in the study, stratified by treatment group (intervention versus 
control) are presented as proportions for binary variables and means (+ standard deviations) or 
medians (minimums, maximums) for continuous variables.  Proportions of women with 
lymphedema, as defined by water displacement, sum of circumferences, bioimpedance 
spectroscopy and survey have been calculated for each method and combination of methods.  
The Chi square test and Fisher exact test were used to compare categorical variables, while 
continuous variables were compared with the Student t-test and Wilcoxin rank sum test.  A 
change of >5%, >5%, >10% and >1 unit in interlimb volume difference, interlimb size difference, 
interlimb impedance ratio and survey score, respectively, was a priori defined as being clinically 
relevant.  Cumulative incidence ratios (relative risks) of outcomes are shown with 95% 
confidence intervals (CIs). Analyses were stratified by lymphedema status and only women with 
complete data, as determined separately for each diagnostic method, were included.  All 
statistical techniques were two sided using Stata 11.0 Data Analysis and Statistical Software 
(StataCorp, College Station, Texas; 2009).    
 
RESULTS 
Participant characteristics 
A total of 295 women were randomly allocated to the weight lifting (n=148) or control (n=147) 
group.  There were no clinical or statistical differences in personal and treatment characteristics 
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between the weight lifting and control group (Table 1).  Mean age was 55 and 57 years for the 
weight lifting and control groups, respectively, and approximately 50% were treated for stage I 
breast cancer, with time since diagnosis being about 50 months.  The majority of the women 
(>70%) had received chemotherapy, radiation therapy and/or hormone therapy, and on average 
about 10 lymph nodes were excised as part of the surgical treatment for their breast cancer.  
For the 71 women in the weight lifting group and the 70 women in the control group defined as 
having lymphedema according to the PAL trial definition, median time since lymphedema 
diagnosis was 45 (1, 183) and 56 (2, 170) months, respectively.  Approximately 40% of these 
women had lymphedema for between 1-3 years, while around 60% had it for more than 3 years.  
 
Details of baseline lymphedema status  
Baseline lymphedema characteristics were similar between the weight lifting and control groups, 
irrespective of diagnostic criteria applied (Table 2). The proportions of women considered to 
have lymphedema at baseline differed according to the diagnostic method used and criteria 
applied (Table 3). When criteria were used independently, proportions considered to have 
lymphedema at baseline ranged between 22-52%. When women had to meet at least two or 
more diagnostic criteria, in particular when either the sum of arm circumference or the BIS 
criteria were included, proportions with lymphedema at baseline were typically around 20%.  
Importantly, all those women with clinical evidence of lymphedema according to the 
circumference method were also identified by the volumetric and Norman survey method. In 
contrast, 12% of those with lymphedema according to the BIS criteria do not self-report 
lymphedema, and 11% and 29% do not have measurable size difference according to the 
volumetric and circumference method, respectively.   
 
Effect of weight lifting on lymphedema status 
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There was no significant difference between the two groups in the proportion of women who had 
a change in interlimb swelling, interlimb size, interlimb ratio or survey score of >5%, >5%, >10% 
and 1 unit, respectively (Table 4). This result did not change when stratified for women with and 
without lymphedema according to the separate diagnostic criteria (results not shown, available 
on request).  There was also no difference in the proportions of women who experienced 
clinically significant declines in their interlimb volume difference, size, ratio or survey score.   
 
DISCUSSION 
The PAL trial’s definition for lymphedema identified 48% (n=141) of the 295 participants as 
having lymphedema.  However, when specific diagnostic criteria were independently applied to 
the cohort, lymphedema was considered clinically evident in between 22% (sum of 
circumferences) - 52% (Norman survey) of participants, and while there is some agreement 
between the methods, when all four criteria are applied only 19% are considered to have 
lymphedema.  These results are in line with that reported by others [13-15], and support the 
notion that differences in diagnostic methods and criteria contribute to variations in findings from 
lymphedema cohort and intervention studies. It is clearly important to therefore consider the 
strengths and limitations of each criteria in light of the cohort under consideration as well as the 
timing at which that cohort is being assessed.   
 
Early lymphedema is characterized by an increase in extracellular fluid.  Measures such as 
water displacement, circumferences and perometry, irrespective of whether the raw data are 
converted into limb volume, assess limb size rather than limb fluids.  Hence, these techniques 
suffer an inherent and unavoidable loss in precision for the detection of early lymphedema, as 
they measure the volume of the entire limb to detect small changes in the volume of the 
extracellular fluid, which accounts for approximately 25% of total limb volume [16]. In contrast, 
bioimpedance spectroscopy provides a surrogate measure of extracellular fluid in the measured 
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limbs rather than total limb volume and has been shown in a prospective, longitudinal, study to 
detect the onset of lymphedema up to 10 months before the condition could be clinically 
diagnosed [23].  However, for those with later-stage non-pitting lymphedema, whereby 
increases in extracellular fluid have been replaced by the deposition of fatty or fibrotic tissue (as 
in non-pitting lymphedema), the bioimpedance spectroscopy interlimb ratio can no longer 
distinguish between those with and without lymphedema. In this scenario, measures of limb size 
can clearly identify this subgroup. Of note, 77 PAL trial participants had non-pitting 
lymphedema, and while the water displacement method detects all of these cases, the BIS 
method was unable to detect 90% of these. Self-report methods allow women to consider 
lymphedema-associated symptoms over an extended period of time, as compared with 
objective measures, which assess lymphedema status at a single point in time.  This is 
important as lymphedema, particularly early lymphedema, may fluctuate over time [12] and thus 
not be captured by a single objective assessment. Unfortunately though, lymphedema 
symptoms are common in women with breast cancer but do not always result in a diagnosis 
upon further examination [17]. Consequently, there is a risk of misclassification when self-report 
measures are used independently of other measures. Clearly these are important 
considerations when choosing the most appropriate diagnostic method, or combination of 
methods, for use in research or the clinical setting.   
 
The majority of women with lymphedema in the PAL trial (according to the trial definition) had 
persistent lymphedema, whereby they had lived with lymphedema for longer than 1 year (60% 
had lymphedema for more than 3 years, and over 30% for between 1-3 years).  Very few of the 
women had been diagnosed with lymphedema in the previous year.  Consequently, these 
women were beyond the preclinical phases of lymphedema development; their lymphedema 
was visible and they had a history of lymphedema treatment, making volumetric and 
circumference measures an appropriate method for assessing lymphedema status and 
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evaluating the potential effect of weight lifting.  However, the PAL sample also included 154 
women who had been treated for breast cancer between 1-15 years prior, all of whom had 
lymph nodes excised (61% had more than 5 nodes removed), and who were therefore at 
elevated risk of developing lymphedema. Bioimpedance spectroscopy was included as an 
additional lymphedema diagnostic method because it provides a sensitive measure of detecting 
lymphedema development in the non-lymphedema group and is also an appropriate measure 
for those with pitting lymphedema.  Finally, the Norman survey was included as a means of 
assessing self-perceived differences in limb size in acknowledgement that women’s perception 
of lymphedema development, exacerbation or improvement are just as important as detecting 
any clinical change.  Outcomes from the PAL trial, using interlimb volume differences, 
symptoms, and clinical evaluations as the outcomes, and using women’s lymphedema status 
classified according to the trial’s definition, have been previously reported [18,19] and have 
demonstrated that weight lifting is safe in those with lymphedema and may prevent the 
development of lymphedema in women with 5 or more lymph nodes excised.  However, it is 
paramount to test the robustness of these conclusions, with different diagnostic criteria applied. 
 
Irrespective of the lymphedema diagnostic criteria used, weight lifting did not initiate nor 
exacerbate lymphedema.  These are important findings, highlighting that progressive weight 
lifting is safe following breast cancer, for those with and at risk for lymphedema.  It also 
highlights that women should be encouraged, and not restricted, to participate in such 
programs, as a means of optimizing function, quality of life, and potentially survival.  The 
incidences of improvements in lymphedema were similar between the weight lifting and control 
group, suggesting that weight lifting may not be an effective means of treating lymphedema.  
However, the ability of specific exercise programs, such as the one evaluated here, to 
effectively manage or mitigate lymphedema may be dependent on the stage of lymphedema 
and should be a topic for future investigation. Further this trial was not powered to evaluate 
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prevention of lymphoedema, nor was it implemented on the ideal breast cancer cohort to 
demonstrate prevention.  Others have demonstrated the ability to prevent lymphoedema using 
physiotherapy-based programs, which have included upper-body exercises, and that started 
within weeks following breast cancer surgery [24,25].  With more research, we will better 
understand, the extent to which programs such as these, as well as the weight training program 
investigated here, will help prevent and/or minimize breast cancer-treatment associated 
concerns, such as lymphedema, as well as optimize function and quality of life during and 
following treatment and potentially survival. 
 
In summary, while the quest for identifying the gold standard in measuring lymphedema 
continues, current various diagnostic methods can be used to our advantage.  The PAL trial and 
the lymphedema characteristics of the participants highlights the importance of using multiple 
diagnostic methods to comprehensively evaluate the impact of an intervention (within the 
research or clinical setting) on lymphedema.  Future lymphedema research must consider the 
potential impact of their method of lymphedema measurement and discuss their findings in light 
of the measure(s) used.  Only then will we be better placed to understand which prevention and 
treatment strategies truly are effective and safe.       
13 
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Table 1: Baseline characteristics of PAL study participants 
  Weight 
Lifting 
(N=148) 
Control 
(n=147) 
Characteristics  N(%) or means+SD or 
medians (min, max) 
P‐value
Age (years)  55.3 (8.5)  56.7 (9.1)  0.19
Education     
  High school or less  20 (13.5)  27 (18.4)  0.47
  Some college  54 (36.5)  47 (32.0) 
 College or more  74 (50.0)  73 (49.6) 
Race     
  White  90 (60.8)  101 (68.7)  0.06
  Black  47 (31.8)  43 (29.3) 
  Other  11 (7.4)  3 (2.0) 
Months since breast cancer diagnosis 
  47 (16, 183)  52 (11, 182)  0.10
Years since lymphedema diagnosisa 
  < 1 year 
  1‐3 years 
  >3 years 
2 (2.9) 
27 (39.7) 
39 (57.4) 
7 (10.2) 
21 (30.4) 
41 (59.4) 
Cancer stage     
  0  1 (0.7)  4 (2.7) 
  I  81 (54.7)  76 (51.7) 
  II  15 (10.1)  9 (6.1) 
  III  50 (33.8)  58 (39.5) 
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  unknown  1 (0.7)   
Number of nodes removed   9.5 (2, 38)  11 (2, 38)  0.42
Chemotherapy (yes)  115 (77.7)  109 (74.2)  0.48
Radiation (yes)  118 (79.7)  111 (75.5)  0.39
Current use of Aromatase Inhibitors or Tamoxifen (yes) 
   104 (70.3)  91 (61.9)  0.13
Treated on dominant side (yes)  73 (49.3)  66 (44.9)  0.48
* lymphedema diagnosis according to PAL criteria; missing data for 4 
women (3=weight lifting, 1=control)  
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Table 2: Baseline lymphedema status of PAL participants 
Lymphedema diagnostic criteria  Weight Lifting 
(N=148) 
Control 
(n=147) 
P value
  N(%) or medians (min, max) 
Volumetric interlimb % difference   4.5 (‐11.1, 61.5)  3.4 (‐11.1, 77.7)  0.83
Circumference interlimb % difference   1.1 (‐6.0, 22.4)  0.9 (‐5.2, 26.6)  0.51
Bioimpedance spectroscopy interlimb ratio  1.01 (0.88, 1.78)  1.02 (0.89, 1.74)  0.39
Norman survey      
  Score  0 (0, 12)  2 (0, 12)  0.60
  Classification:     
    No LE  70 (47.3)  74 (50.4)  0.80
    Mild  18 (12.2)  19 (12.9) 
    Moderate+  60 (40.5)  54 (36.7) 
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Table 3: Proportions of women in the PAL trial with lymphedema according to various diagnostic 
criteria 
Single diagnostic criteria  N  % 
Volumetric interlimb volume difference >5% (Vol)  132  46.5 
Circumference interlimb size difference >5% (Circ)  62  21.8 
Bioimpedance spectrocopy interlimb ratio >3 standard      
deviation of normative values (BIS) 
76  26.8 
Norman survey – scores 1+ (Norman)  147  51.8 
Combined diagnostic criteria     
Vol + Circ  62  21.8 
Vol + BIS  68  23.9 
Vol + Norman  105  37.0 
Circ + BIS  54  19.0 
Circ + Norman  62  21.8 
BIS + Norman  65  22.9 
Vol + Circ + BIS  54  19.0 
Vol + Circ + Norman  62  21.8 
Vol + BIS + Norman  62  21.8 
Circ + BIS + Norman  54  19.0 
Volume + Circ + BIS + Norman  54  19.0 
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Table 4 Lymphedema outcomes at 12 months a 
Lymphedema 
diagnostic criteria 
Weight lifting 
group 
Control group  Cumulative incidence 
ratio or mean differences 
(95% CI) 
 
  n (%)  n (%)    P value
Change in interlimb volume differenceb 
>5% increase  16 (12.2)  21 (15.9)  0.8 (0.4‐1.4)  0.39
>5% decrease  19 (14.5)  25 (18.9)  0.8 (0.4‐1.3)  0.34
Change in interlimb sum of circumference differenceb   
>5% increase  0 (0)  3 (2.3)  ‐              ‐ 
>5% decrease  3 (2.3)  1 (0.75)  3.1 (0.32 – 28.91)  0.37
Change in interlimb ratiob 
>10% increase  4 (3.7)  5 (4.7)  0.8 (0.2‐2.9)  0.75
>10% decrease  3 (2.8)  7 (6.5)  0.4 (0.1‐1.6)  0.21
Change in Norman scoreb 
>1 unit increase  4 (3.1)  7(5.3)  0.6 (0.2‐1.9)  0.54
>1 unit decrease  66 (50.4)  59 (44.7)  1.1 (0.9‐1.5)  0.36
a women with complete data for each particular outcome were included in the analysis; b a 5%, 5%, 
10% and 1 unit change in interlimb volume, interlimb sum of circumference difference, interlimb ratio 
and Norman score, respectively, is considered clinically relevant. 
 
